5 unknown, 1 completed, 1 recruiting, 1 terminated. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Unknown 5, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Unknown 2, Terminated 1 |
Follow dalpiciclib: new trials by email Literature Review of dalpiciclib trials Research Report on dalpiciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IN10018 in Combination With Dalpiciclib for Progressive Meningiomas Ifebemtinib, Dalpiciclib - Meningioma, CDK4/6 Inhibitor | Phase 1 | Recruiting | Capital Medical University | 24 | 2026-08-31 | 2026-10-21 |
| Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg - Esophageal Squamous Cell Carcinoma | Phase 1 | Unknown | West China Hospital | 6 | 2023-12-29 | 2024-03-06 |
| Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas Camrelizumab, Dalpiciclib 100mg, Dalpiciclib 150mg - Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | West China Hospital | 6 | 2023-10-31 | 2024-07-23 |
| Study of SHR6390 in Renal Insufficiency and Healthy Subjects SHR6390 - Breast Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 30 | 2022-12-18 | 2023-03-10 |
| Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study Dalpiciclib, Chidamide - HR+/HER2- Advanced Breast Cancer | Phase 1 | Completed | Beijing 302 Hospital | 22 | 2022-10-01 | 2026-05-29 |
| Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer Dalpiciclib, Fulvestrant, Pertuzumab - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 72 | 2022-09-01 | 2024-02-26 |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer Famitinib, SHR6390, Fulvestrant - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Henan Cancer Hospital | 46 | 2021-12-08 | 2024-12-17 |
| Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer Dalpiciclib, Pyrotinib, Letrozole - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 59 | 2019-05-12 | 2023-03-07 |
Breast Neoplasms (4) · Esophageal Squamous Cell Carcinoma (1) · Meningioma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Fudan University (2) · West China Hospital (2) · Beijing 302 Hospital (1) · Capital Medical University (1) · Henan Cancer Hospital (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
China (8)
Jin Zhou, MD.,PhD. (2) · Hongwei Zhang, MD, PhD (1) · Min Yan (1)